Fresenius Kabi, a global health care company based in Lake Zurich, said Friday that a new oncology drug is now available in the U.S.
Fresenius Kabi Bortezomib for Injection is available as a single dose vial containing 3.5 mg of lyophilized powder.
The drug is the first and only available alternative for intravenous use and expands the company's extensive oncology portfolio.
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
"Fresenius Kabi Bortezomib is a cost efficient product alternative for our customers and the patients they treat. We are proud to offer an expansive oncology portfolio and will continue to develop these essential medicines," said John Ducker, president and CEO of Fresenius Kabi USA.
Fresenius Kabi Bortezomib for Injection for intravenous use is indicated for the treatment of patients with multiple myeloma and for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.
Bortezomib for Injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boric acid or glycine, including anaphylactic reactions; contraindicated for intrathecal administration -- fatal events have occurred.